Meeting
2015 ASCO Annual Meeting
Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly.
Authors
Ignazio Ugo Carreca
University of Palermo, Palermo, Italy
Ignazio Ugo Carreca , Giuseppe Bronte , Anna Paola Carreca , Viviana Bazan , Dario Cova , Antonio Russo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Geriatric Oncology
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9540)
DOI
10.1200/jco.2015.33.15_suppl.9540
Abstract #
9540
Poster Bd #
199
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Baseline comprehensive geriatric assessment to predict for toxicity of single-agent chemotherapy in elderly metastatic breast cancer patients: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group.
First Author: Marije Hamaker
Poster
2011 ASCO Annual Meeting
The relationship between age and survival outcomes for eribulin in metastatic breast cancer.
First Author: C. Twelves
Poster
2022 ASCO Quality Care Symposium
Impact of the Cancer and Aging Research Group (CARG) chemotherapy toxicity (tox) risk score on the benefit of a geriatric assessment–driven intervention (GAIN) among older adults with cancer.
First Author: Christiana Crook
Poster
2022 ASCO Annual Meeting
Remote geriatric assessment program for older patients starting new chemotherapy treatment in Brazil.
First Author: Cristiane Decat Bergerot